Kymera Therapeutics (NASDAQ:KYMR) Sets New 12-Month Low – Here’s Why

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $26.99 and last traded at $28.23, with a volume of 32523 shares trading hands. The stock had previously closed at $29.62.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. BTIG Research assumed coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price target for the company. Citigroup started coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 target price for the company. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Friday, December 27th. BMO Capital Markets assumed coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price target on the stock. Finally, Stephens restated an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $56.36.

Kymera Therapeutics Stock Performance

The company’s 50 day moving average price is $35.23 and its 200-day moving average price is $41.48. The stock has a market cap of $1.64 billion, a P/E ratio of -10.79 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. On average, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Kymera Therapeutics

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,788 shares of company stock valued at $455,202. 15.82% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KYMR. Thrivent Financial for Lutherans purchased a new position in Kymera Therapeutics in the third quarter valued at approximately $313,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Kymera Therapeutics by 8.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after buying an additional 915 shares during the last quarter. PEAK6 Investments LLC grew its stake in shares of Kymera Therapeutics by 15.4% during the 3rd quarter. PEAK6 Investments LLC now owns 15,000 shares of the company’s stock worth $710,000 after acquiring an additional 2,000 shares during the period. Walleye Capital LLC purchased a new stake in Kymera Therapeutics in the 3rd quarter worth about $472,000. Finally, Erste Asset Management GmbH purchased a new stake in Kymera Therapeutics in the 3rd quarter worth about $1,315,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.